Related Experiment Video
Updated: Dec 13, 2025
06:22
Contractility Measurements on Isolated Papillary Muscles for the Investigation of Cardiac Inotropy in Mice
Published on: September 17, 2015
15.3K
What Inotrope and Why?
1Department of Neonatology, John Hunter Children's Hospital, Lookout Road, New Lambton Heights, New South Wales 2305, Australia; University of Newcastle, Newcastle, Australia.
Clinics in Perinatology
|July 28, 2020
Summary
Inotrope therapy for cardiovascular compromise in neonates has limited impact on mortality. Prevention strategies are crucial, and further research into neonatal cardiovascular therapy is needed.
Area of Science:
- Neonatal cardiovascular physiology
- Pharmacology of inotropes
Background:
- The cardiovascular system's primary role is meeting metabolic demands.
- Inotrope therapy aims to mitigate cardiovascular compromise.
- Current inotrope use relies on pathophysiology and drug action understanding.
Purpose of the Study:
- To evaluate the effectiveness of current inotrope therapy in reducing morbidity and mortality.
- To identify gaps in understanding circulatory targets and inotrope selection.
- To emphasize the need for advanced neonatal cardiovascular therapies.
Main Methods:
- Review of current inotrope therapy practices in neonates.
- Analysis of morbidity and mortality data associated with cardiovascular compromise.
- Identification of knowledge gaps in neonatal circulatory physiology and pharmacology.
Main Results:
- Inotrope therapy has not significantly reduced morbidity and mortality in neonates with cardiovascular compromise.
- There are substantial gaps in understanding optimal circulatory targets, thresholds, and inotrope choices.
- Prevention of cardiovascular compromise is currently the most effective strategy.
Conclusions:
- Current inotrope therapy approaches require re-evaluation.
- Further research with alternative study designs is essential for advancing neonatal cardiovascular therapy.
- Preventive measures are paramount for improving outcomes in neonates with cardiovascular compromise.
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.7K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.4K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
01:14Active Transport
1.8K
Active transport is a critical biological process that allows cells to move solutes against an electrochemical gradient. This process requires direct energy input and is characterized by its selectivity, saturability, and susceptibility to competitive inhibition.
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
1.8K
01:18Adrenergic Agonists: Therapeutic Classification
1.3K
Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
1.3K
01:17Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
2.6K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.6K